Pencil-beam scanning proton re-irradiation showed low acute toxicity in recurrent head and neck cancer
Pencil-beam scanning proton re-irradiation achieved 17.2-month median survival with 7.7% grade 3 or higher oral mucositis.
Pencil-beam scanning proton re-irradiation achieved 17.2-month median survival with 7.7% grade 3 or higher oral mucositis.
SMART-BRAIN proton planning spared portions of non-target brain while maintaining target coverage in five medulloblastoma cases.
High-dose-rate brachytherapy monotherapy achieved 86% biochemical control at median 13-year follow-up in localized prostate cancer.
Prophylactic cranial irradiation was associated with longer survival and brain metastasis-free survival than magnetic resonance imaging surveillance.
Deep learning auto-segmentation reduced editing, but both minimal and excessive manual edits were associated with lower clinical acceptability.
A decision tree model identified interleukin-8, hemoglobin, and lymphocyte count as key survival predictors after palliative radiotherapy.
Artificial intelligence planning produced clinically acceptable whole-brain radiotherapy plans in 14 of 15 independent test cases.
Same-day hyaluronic acid rectal spacer placement reduced rectal dose while preserving ultrasound-based prostate brachytherapy planning.
An artificial intelligence coronary artery surrogate strongly correlated with manual dose metrics in simulated lung stereotactic body radiotherapy.
Tumor treating field arrays caused substantial surface dose enhancement and measurable dose attenuation during 6-megavolt photon irradiation.
Immuno-Eclipse radiotherapy improved bulky tumor control in mice through natural killer and cytotoxic T-cell immunity.
Gamma Knife radiosurgery achieved 73.53% 5-year progression-free survival in a small postoperative papillary craniopharyngioma cohort.
A multi-regional clinical-radiomics model reached an external-test area under the curve of 0.908 for 5-year recurrence prediction.
A multimodal imaging, radiomics, and clinical deep learning model showed moderate external validation for survival risk after Gamma Knife radiosurgery.
A single-arm phase 1/2 trial reported a 39.1% pathologic complete response rate among resected patients, with grade 4 toxicities in 10%.